WallStSmart

Bioceres Crop Solutions Corp (BIOX)vsCorteva Inc (CTVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Corteva Inc generates 5369% more annual revenue ($17.40B vs $318.16M). CTVA leads profitability with a 6.3% profit margin vs -17.7%. CTVA appears more attractively valued with a PEG of 1.13. CTVA earns a higher WallStSmart Score of 52/100 (C-).

BIOX

Hold

50

out of 100

Grade: D+

Growth: 7.3Profit: 3.0Value: 6.7Quality: 5.0

CTVA

Buy

52

out of 100

Grade: C-

Growth: 4.0Profit: 5.0Value: 8.7Quality: 6.0
Piotroski: 4/9Altman Z: 1.49
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BIOX.

CTVAUndervalued (+8.0%)

Margin of Safety

+8.0%

Fair Value

$81.90

Current Price

$82.03

$0.13 discount

UndervaluedFair: $81.90Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BIOX2 strengths · Avg: 9.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

EPS GrowthGrowth
34.4%8/10

Earnings expanding 34.4% YoY

CTVA5 strengths · Avg: 8.4/10
Market CapQuality
$54.19B9/10

Large-cap with strong market position

Debt/EquityHealth
0.119/10

Conservative balance sheet, low leverage

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

EPS GrowthGrowth
27.4%8/10

Earnings expanding 27.4% YoY

Free Cash FlowQuality
$4.15B8/10

Generating 4.2B in free cash flow

Areas to Watch

BIOX4 concerns · Avg: 2.8/10
PEG RatioValuation
1.954/10

Expensive relative to growth rate

Market CapQuality
$23.61M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-19.0%2/10

ROE of -19.0% — below average capital efficiency

Revenue GrowthGrowth
-16.4%2/10

Revenue declined 16.4%

CTVA4 concerns · Avg: 2.5/10
Return on EquityProfitability
5.0%3/10

ROE of 5.0% — below average capital efficiency

Profit MarginProfitability
6.3%3/10

6.3% margin — thin

P/E RatioValuation
46.0x2/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
-1.7%2/10

Revenue declined 1.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : BIOX

The strongest argument for BIOX centers on Price/Book, EPS Growth.

Bull Case : CTVA

The strongest argument for CTVA centers on Market Cap, Debt/Equity, Price/Book. PEG of 1.13 suggests the stock is reasonably priced for its growth.

Bear Case : BIOX

The primary concerns for BIOX are PEG Ratio, Market Cap, Return on Equity.

Bear Case : CTVA

The primary concerns for CTVA are Return on Equity, Profit Margin, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.

Key Dynamics to Monitor

BIOX profiles as a turnaround stock while CTVA is a value play — different risk/reward profiles.

CTVA carries more volatility with a beta of 0.72 — expect wider price swings.

CTVA is growing revenue faster at -1.7% — sustainability is the question.

CTVA generates stronger free cash flow (4.2B), providing more financial flexibility.

Bottom Line

CTVA scores higher overall (52/100 vs 50/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bioceres Crop Solutions Corp

BASIC MATERIALS · AGRICULTURAL INPUTS · USA

Bioceres Crop Solutions Corp.

Corteva Inc

BASIC MATERIALS · AGRICULTURAL INPUTS · USA

Corteva, Inc. (also known as Corteva Agriscience) is a major American agricultural chemical and seed company that was the agricultural unit of DowDuPont prior to being spun off as an independent public company.

Visit Website →

Want to dig deeper into these stocks?